Nuvation Bio NUVB
NYSE NUVB
$4.21 -0.14 (-3.22%)
As of: Nov 10, 2026 · 3:59 PM EST

Nuvation Bio (NUVB) Convertible Debt (2026)

Updated

Nuvation Bio (NUVB) posted Convertible Debt of $242.62 million for Q2 2026.

Analysis

Nuvation Bio (NUVB) Convertible Debt (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Nuvation Bio 1.51 Bn -881.30 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 279.46 Mn
Jun 30, 2026 242.62 Mn
API Access

Nuvation Bio Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=NUVB&period=max&api_key=YOUR_API_KEY